What is the acute and long‑term management of methylmalonic acidemia in children?

Management of Methylmalonic Acidemia in Children

Methylmalonic acidemia requires immediate aggressive treatment during acute decompensation with protein restriction, high-calorie support, and management of hyperammonemia, followed by long-term dietary protein restriction, carnitine supplementation, and consideration of hydroxycobalamin for cobalamin-responsive subtypes, with liver transplantation reserved for patients with recurrent metabolic crises refractory to medical management. 1, 2

Acute Management During Metabolic Decompensation

Immediate Interventions

• Stop all protein intake immediately and provide high-calorie support (glucose infusions at 10-15 mg/kg/min) to prevent catabolism and halt the accumulation of toxic metabolites 1, 2
• Administer L-carnitine supplementation (100-400 mg/kg/day IV during acute episodes) to facilitate excretion of toxic acyl-CoA intermediates 1
• Monitor and treat hyperammonemia aggressively if ammonia levels exceed 100 µmol/L in neonates or ≥50 µmol/L in older children 3

Hyperammonemia Management

When hyperammonemia complicates MMA (occurring due to secondary inhibition of N-acetylglutamate synthase), the approach must be escalated based on severity 3:

• For ammonia >200 µmol/L or hyperammonemic coma: Initiate kidney replacement therapy immediately, as these levels are associated with poor neurological outcomes 3
• Continuous kidney replacement therapy (CKRT) achieved 60% success rates in reducing ammonia to normal levels in MMA patients, while intermittent hemodialysis showed 100% success but in smaller patient numbers 3
• Peritoneal dialysis had only 65% success rates and should be considered second-line 3

Cofactor Therapy

• Administer intramuscular hydroxycobalamin (1 mg daily initially, then adjusted based on response) for all newly diagnosed patients to identify cobalamin-responsive subtypes (mut- variants) 4, 1
• Subcutaneous administration is an alternative route when intramuscular injection is contraindicated 4

Adjunctive Therapy for Hyperammonemia

• N-carbamylglutamate (carglumic acid) at doses as low as 50-100 mg/kg/day can maintain normal ammonia levels during acute episodes and prevent recurrent decompensations 5
• This therapy specifically addresses the secondary inhibition of the urea cycle that occurs in MMA 5

Long-Term Management

Dietary Management

• Restrict natural protein intake to 1.0-1.5 g/kg/day (adjusted based on age, growth, and metabolic control) while ensuring adequate caloric intake for age 1, 2
• Use medical foods (protein-free formulas supplemented with amino acid mixtures lacking isoleucine, valine, methionine, and threonine), though evidence for their benefit requires prospective controlled studies 2
• Maintain adequate caloric intake to prevent endogenous protein catabolism 1

Chronic Supplementation

• Continue L-carnitine (100 mg/kg/day orally, divided doses) indefinitely to facilitate excretion of propionyl-CoA derivatives 1
• Maintain hydroxycobalamin (1 mg intramuscularly 1-2 times weekly) for cobalamin-responsive patients 1
• Consider long-term N-carbamylglutamate at the lowest effective dose (as low as 50 mg/kg/day) to prevent hyperammonemic episodes 5

Monitoring for Complications

Neurological surveillance is critical, as progressive basal ganglia injury can occur even with optimal metabolic control 1, 2:

• Monitor for extrapyramidal movement disorders (tremor, dystonia, chorea) 1
• Metabolic strokes targeting the basal ganglia occur during metabolic stress despite optimal management 2
• Developmental delay and cognitive decline may progress 1, 6

Renal function monitoring must be performed regularly, as chronic renal failure develops in a major subset of patients through unclear mechanisms 1:

• Check serum creatinine, BUN, and urinalysis every 3-6 months 1
• Hemodialysis may become necessary for end-stage renal disease 1

Cardiac screening should include echocardiography every 6-12 months to detect cardiomyopathy 4, 2

Ophthalmological examination annually to screen for optic neuropathy 2

Hematological monitoring for neutropenia, anemia, and rare but serious hemophagocytic lymphohistiocytosis (HLH) 6:

• Elevated serum ferritin during acute decompensations may indicate HLH, which requires immediate recognition and treatment 6
• Ferritin correlates strongly with propionylcarnitine levels during attacks 6

Liver Transplantation

Liver transplantation should be considered for patients with recurrent, life-threatening metabolic decompensations despite optimal medical management 2, 7:

• Benefits: Reduces frequency of metabolic crises, allows relaxed protein diet, lowers (but does not normalize) plasma and urine MMA levels, and improves quality of life 7
• Limitations: Does not prevent or reverse neurological damage, does not stop progression of renal dysfunction, and metabolic strokes can still occur post-transplant 2, 7
• Post-transplant management: Continue medical foods and metabolic monitoring, as transplantation does not cure the disease 7

Combined kidney-liver transplantation may be necessary for patients with concurrent end-stage renal disease, though experience remains limited 1, 7

Common Pitfalls

• Failure to recognize acute decompensation early: Vomiting, lethargy, and altered mental status require immediate metabolic evaluation and aggressive intervention 3
• Inadequate caloric support during illness: Even brief periods of catabolism can trigger severe metabolic crises 1
• Missing cobalamin-responsive subtypes: All patients should receive a trial of hydroxycobalamin, as mut- variants show significant improvement 1
• Underestimating neurological risk: Basal ganglia injury can occur even with "optimal" metabolic control during intercurrent illnesses 2
• Overlooking HLH: Unexplained fever, cytopenias, and markedly elevated ferritin during decompensation should prompt evaluation for this rare but life-threatening complication 6